{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T02:21:50Z","timestamp":1770776510332,"version":"3.50.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.hoc.2016.11.009","type":"journal-article","created":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T16:52:00Z","timestamp":1490287920000},"page":"189-207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Peripheral T-Cell Lymphoma, Not Otherwise Specified"],"prefix":"10.1016","volume":"31","author":[{"given":"Musa","family":"Al-Zahrani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2016.11.009_bib1","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissue","author":"Swerdlow","year":"2008"},{"issue":"5","key":"10.1016\/j.hoc.2016.11.009_bib2","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A\u00a0revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.009_bib3","article-title":"World Health Organization classification: tumours of hematopoetic and lymphoid tissues","author":"Jaffe","year":"2001"},{"issue":"3","key":"10.1016\/j.hoc.2016.11.009_bib4","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1172\/JCI26833","article-title":"Gene expression analysis of peripheral T\u00a0cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets","volume":"117","author":"Piccaluga","year":"2007","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"10.1016\/j.hoc.2016.11.009_bib5","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1586\/ehm.11.37","article-title":"Peripheral T-cell lymphoma classification: the matter of cellular derivation","volume":"4","author":"Piccaluga","year":"2011","journal-title":"Expert Rev Hematol"},{"issue":"20","key":"10.1016\/j.hoc.2016.11.009_bib6","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2016.11.009_bib7","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.humpath.2013.03.002","article-title":"Distinct morphologic, phenotypic, and clinical-course characteristics of indolent peripheral T-cell lymphoma","volume":"44","author":"Hayashi","year":"2013","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.hoc.2016.11.009_bib8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/bjh.12255","article-title":"Primary peripheral T-cell lymphoma, not otherwise specified of the thyroid with autoimmune thyroiditis","volume":"161","author":"Yoshida","year":"2013","journal-title":"Br J Haematol"},{"issue":"19","key":"10.1016\/j.hoc.2016.11.009_bib9","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2016.11.009_bib10","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2016.11.009_bib11","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","article-title":"The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells","volume":"109","author":"de Leval","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2016.11.009_bib12","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/sj.leu.2403960","article-title":"Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas","volume":"19","author":"Martinez-Delgado","year":"2005","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.hoc.2016.11.009_bib13","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1158\/1078-0432.CCR-04-0269","article-title":"Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes","volume":"10","author":"Martinez-Delgado","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"Supp 5","key":"10.1016\/j.hoc.2016.11.009_bib14","first-page":"124a","article-title":"Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas","volume":"16","author":"Ballester","year":"2005","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.hoc.2016.11.009_bib15","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1200\/JCO.2006.09.4474","article-title":"Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas","volume":"25","author":"Cuadros","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.hoc.2016.11.009_bib16","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1200\/JCO.2012.42.5611","article-title":"Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study","volume":"31","author":"Piccaluga","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2016.11.009_bib17","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1182\/blood-2014-02-555763","article-title":"Cellular origin of T-cell lymphomas","volume":"123","author":"de Leval","year":"2014","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.hoc.2016.11.009_bib18","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-04-0371","article-title":"CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified","volume":"10","author":"Ishida","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2016.11.009_bib19","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood-2002-05-1352","article-title":"Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL","volume":"103","author":"Tsuchiya","year":"2004","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.hoc.2016.11.009_bib20","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2013-12-544809","article-title":"GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2016.11.009_bib21","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T\u00a0cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.hoc.2016.11.009_bib22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/leu.2014.261","article-title":"Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis","volume":"29","author":"Schatz","year":"2015","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.hoc.2016.11.009_bib23","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International Peripheral T-Cell and Natural Killer\/T-Cell Lymphoma Study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2016.11.009_bib24","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","article-title":"Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy","volume":"25","author":"Abramson","year":"2014","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2016.11.009_bib25","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish lymphoma registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.hoc.2016.11.009_bib26","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.hoc.2016.11.009_bib27","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A\u00a0predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project","volume":"329","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.hoc.2016.11.009_bib28","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.hoc.2016.11.009_bib29","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","article-title":"Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score","volume":"24","author":"Went","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2016.11.009_bib30","first-page":"76","article-title":"Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA)","volume":"92","author":"Gisselbrecht","year":"1998","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2016.11.009_bib31","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2016.11.009_bib32","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1097\/01.pas.0000173238.17331.6b","article-title":"Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified","volume":"29","author":"Asano","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"13","key":"10.1016\/j.hoc.2016.11.009_bib33","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2006-04-017632","article-title":"Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study","volume":"108","author":"Dupuis","year":"2006","journal-title":"Blood"},{"issue":"Supplement 4","key":"10.1016\/j.hoc.2016.11.009_bib34","first-page":"113a","article-title":"Peripheral T-cell Lymphoma, not otherwise specified: a clinicopathologic study of 340 cases from the International Peripheral T-cell Lymphoma Project","volume":"19","author":"Weisenburger","year":"2008","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.hoc.2016.11.009_bib35","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2016.11.009_bib36","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1038\/bcj.2014.34","article-title":"The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas","volume":"4","author":"Briski","year":"2014","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.hoc.2016.11.009_bib37","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","article-title":"Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T\u00a0cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95","volume":"151","author":"Simon","year":"2010","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.hoc.2016.11.009_bib38","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2016.11.009_bib39","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.3109\/10428194.2014.963078","article-title":"Survival in patients with limited-stage peripheral T-cell lymphomas","volume":"56","author":"Briski","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.hoc.2016.11.009_bib40","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1182\/blood-2003-07-2490","article-title":"Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies","volume":"104","author":"Mahadevan","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2016.11.009_bib41","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/cncr.27733","article-title":"Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350","volume":"119","author":"Mahadevan","year":"2013","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.hoc.2016.11.009_bib42","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/annonc\/mdq635","article-title":"Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma","volume":"22","author":"Kluin-Nelemans","year":"2011","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2016.11.009_bib43","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00277-013-1880-4","article-title":"CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T\u00a0cell lymphomas: final analysis of a prospective phase II trial","volume":"92","author":"Binder","year":"2013","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.hoc.2016.11.009_bib44","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-007-0469-9","article-title":"Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study","volume":"60","author":"Kim","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"10.1016\/j.hoc.2016.11.009_bib45","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.hoc.2016.11.009_bib46","article-title":"Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (pTNHL) of the elderly: final results of 116 patients treated in the international ACT-2 phase III trial","volume":"34","author":"Trumper","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2016.11.009_bib47","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/annonc\/mdv624","article-title":"A\u00a0phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas","volume":"27","author":"Kim","year":"2016","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2016.11.009_bib48","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cncr.20999","article-title":"Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma","volume":"103","author":"Escalon","year":"2005","journal-title":"Cancer"},{"issue":"25","key":"10.1016\/j.hoc.2016.11.009_bib49","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Upfront autologuos stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2016.11.009_bib50","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2016.11.009_bib51","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1046\/j.1365-2141.2003.04203.x","article-title":"Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype","volume":"120","author":"Song","year":"2003","journal-title":"Br J Haematol"},{"issue":"25","key":"10.1016\/j.hoc.2016.11.009_bib52","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2016.11.009_bib53","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000358579","article-title":"Allogeneic stem-cell transplantation for peripheral T-cell lymphoma: a systemic review and meta-analysis","volume":"133","author":"Wei","year":"2015","journal-title":"Acta Haematol"},{"issue":"16","key":"10.1016\/j.hoc.2016.11.009_bib54","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2016.11.009_bib55","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2016.11.009_bib56","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.009_bib57","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J\u00a0Hematol Oncol"},{"issue":"23","key":"10.1016\/j.hoc.2016.11.009_bib58","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral t-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) Study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.hoc.2016.11.009_bib59","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.hoc.2016.11.009_bib60","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell\u00a0lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2016.11.009_bib61","doi-asserted-by":"crossref","first-page":"803a","DOI":"10.1182\/blood.V124.21.803.803","article-title":"Duvelisib (IPI-145), a phosphoinositide-3-kinase-\u03b4,\u03b3 inhibitor, shows activity in patients with relapsed\/refractory T-cell lymphoma","volume":"124","author":"Horwitz","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2016.11.009_bib62","first-page":"95","article-title":"Phase 2 Trial of Alisertib (MLN8237), an investigational, potent inhibitor of aurora A kinase (AAK), in patients (pts) with aggressive B- and T-cell non-Hodgkin lymphoma (NHL)","volume":"118","author":"Friedberg","year":"2011","journal-title":"ASH Annu Meet Abstr"},{"issue":"21","key":"10.1016\/j.hoc.2016.11.009_bib63","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1200\/JCO.2014.60.6327","article-title":"Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108","volume":"33","author":"Barr","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.hoc.2016.11.009_bib64","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1182\/blood.V126.23.341.341","volume":"126","author":"O'Connor","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2016.11.009_bib65","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.hoc.2016.11.009_bib66","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in Patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858816301770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858816301770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:04:17Z","timestamp":1760184257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858816301770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0889858816301770"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2016.11.009","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral T-Cell Lymphoma, Not Otherwise Specified","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2016.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}